We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+56.37%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$102M
AUM Growth
+$17M
Cap. Flow
-$11.6M
Cap. Flow %
-11.47%
Top 10 Hldgs %
53.57%
Holding
52
New
16
Increased
7
Reduced
8
Closed
17

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$5.53M
2
SMMT icon
Summit Therapeutics
SMMT
+$4.78M
3
CDTX
Cidara Therapeutics
CDTX
+$4.37M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.62M
5
IQV icon
IQVIA
IQV
+$3.48M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$7.13M
2
VRNA
Verona Pharma
VRNA
+$6.52M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$5.1M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$4.74M
5
TVTX icon
Travere Therapeutics
TVTX
+$4.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
26
Scholar Rock
SRRK
$6.2B
$1.47M 1.45%
+39,521
New +$1.38M
PTGX icon
27
Protagonist Therapeutics
PTGX
$8.49B
$1.35M 1.33%
+20,358
New +$1.16M
TVTX icon
28
Travere Therapeutics
TVTX
$5.14B
$1.28M 1.26%
53,627
-222,847
-81% -$4.19M
ORIC icon
29
Oric Pharmaceuticals
ORIC
$1.11B
$1.07M 1.06%
89,346
-255,576
-74% -$2.69M
RAPT
30
DELISTED
RAPT Therapeutics
RAPT
$888K 0.88%
34,449
+8,415
+32% +$110K
VIR icon
31
Vir Biotechnology
VIR
$1.59B
$858K 0.85%
+150,312
New +$769K
CRBP icon
32
Corbus Pharmaceuticals
CRBP
$163M
$729K 0.72%
+57,644
New +$548K
NBP
33
NovaBridge Biosciences American Depositary Shares
NBP
$207M
$529K 0.52%
+139,886
New +$475K
BMEA icon
34
Biomea Fusion
BMEA
$91.1M
$505K 0.5%
250,000
– –
IPSC icon
35
Century Therapeutics
IPSC
$408M
$231K 0.23%
462,963
– –
CYTK icon
36
Cytokinetics
CYTK
$10.9B
– –
-61,103
Closed -$2.02M
IONS icon
37
Ionis Pharmaceuticals
IONS
$9.03B
– –
-98,267
Closed -$3.88M
LQDA icon
38
Liquidia Corp
LQDA
$6.69B
– –
-71,071
Closed -$886K
MLTX icon
39
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-17,623
Closed -$832K
NBIX icon
40
Neurocrine Biosciences
NBIX
$17.2B
– –
-40,608
Closed -$5.1M
OCUL icon
41
Ocular Therapeutix
OCUL
$2.01B
– –
-88,980
Closed -$826K
RARE icon
42
Ultragenyx Pharmaceutical
RARE
$2.98B
– –
-130,422
Closed -$4.74M
RCKT icon
43
Rocket Pharmaceuticals
RCKT
$372M
– –
-214,412
Closed -$525K
RNAM
44
DELISTED
Avidity Biosciences
RNAM
– –
-47,037
Closed -$1.34M
SLNO
45
DELISTED
Soleno Therapeutics
SLNO
– –
-33,691
Closed -$2.82M
SLNO
46
PUT
DELISTED
Soleno Therapeutics
SLNO
– –
-50,000
Closed -$4.19M
SY
47
So-Young International
SY
$170M
– –
-72,936
Closed -$226K
UTHR icon
48
United Therapeutics
UTHR
$22.5B
– –
-4,874
Closed -$1.4M
VRNA
49
DELISTED
Verona Pharma
VRNA
– –
-68,982
Closed -$6.52M
WVE icon
50
Wave Life Sciences
WVE
$1.09B
– –
-70,242
Closed -$457K
1
2
3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Superstring Capital Management held 52 positions worth $102M, up 20% from $84.5M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Superstring Capital Management withdrew a net $11.6M in Q3 2025, closing 17 positions and reducing 8 holdings. Its most notable exit was Verona Pharma, an estimated $6.52M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Immunovant worth $5.5M.

  • Superstring Capital Management's largest Q3 2025 buy was Immunovant: 341,348 shares worth $5.5M.
  • Superstring Capital Management added most to Zai Lab in Q3 2025, an estimated $2.26M increase.
  • Superstring Capital Management's biggest Q3 2025 reduction was Cogent Biosciences, cutting an estimated $7.13M.
  • Superstring Capital Management fully exited Verona Pharma in Q3 2025, selling an estimated $6.52M.
  • Superstring Capital Management's ten largest holdings make up 54% of its $102M portfolio in Q3 2025.
  • Superstring Capital Management opened 16 new positions and closed 17 in Q3 2025.
  • Superstring Capital Management's portfolio value rose 20% quarter-over-quarter to $102M.

Based on Superstring Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.